AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02132793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anger Management Therapy & RELAX app
Description: Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
Study NCT00408083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiHance
Description: 0.5 mmol/kg as a single dose administration
Study NCT00408083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnevist
Description: 0.5 mmol/kg as a single dose administration
Study NCT01296997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium phosphate
Description: the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
Study NCT01296997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the subjects consumed a bread without pentacalcium phosphate
Study NCT00551018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: one 30 mg tablet QD
Study NCT00551018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine and tenofovir disoproxil fumarate
Description: one 200/300 combination tablet QD
Study NCT01199016 — intervention group
Intervention type: PROCEDURE
Intervention: Tympanocentesis
Description: To be performed as needed on children presenting with acute otitis media
Study NCT01199016 — intervention group
Intervention type: PROCEDURE
Intervention: Nose/throat swab
Description: To be performed at every study visit
Study NCT01199016 — intervention group
Intervention type: BIOLOGICAL
Intervention: Observational
Description: Observational Study Only
Study NCT01313585 — intervention group
Intervention type: DRUG
Intervention: Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device
Study NCT01313585 — intervention group
Intervention type: DRUG
Intervention: Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device
Study NCT01313585 — intervention group
Intervention type: DRUG
Intervention: Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device
Study NCT01313585 — intervention group
Intervention type: DRUG
Intervention: Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI
Study NCT00437359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Toremifene citrate
Description: Toremifene citrate: 40-mg tablets by mouth once daily.
Study NCT00437359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: Anastrozole: 1-mg tablets by mouth once daily.
Study NCT02594865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna
Description: Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
Study NCT02594865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin
Description: Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
Study NCT02467478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: 5 mg tablet once daily for 12 weeks
Study NCT02467478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 12 weeks
Study NCT00478244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Day -9 through Day -6: 1.1 mg/kg if \< 12 kg IV every 6 hours; 0.8 mg/kg if > 12 kg.
Study NCT01960543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl 15 microg
Study NCT01960543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 7 mg
Study NCT01960543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 9 mg
Study NCT01960543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 7 mg
Study NCT01960543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 9 mg
Study NCT02387164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alum-GAD
Description: Two doses à 20 microgram 30 days apart subcutaneously administrated
Study NCT02387164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2000 Units (IE) (50 microgram) vitamin D3 daily
Study NCT02387164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 2000 Units (IE) (50 microgram) vitamin D3 daily
Study NCT04688541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optitip Catheter (LinC Medical)
Description: The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
Study NCT04688541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Foley catheter
Study NCT03695380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
Study NCT03695380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
Study NCT03695380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
Study NCT03739645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety
Description: After fear conditioning the cue induces autonomic responses like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after cueing or conditioning. Activity across blocks in the conditioning stage shows that the skin conductance can be described by levels, and slopes which might be related to state anxiety and trait anxiety (Spielberger trait and state anxiety inventory or questionnaire). These skin conductance measures may be concrete metrics for psychological processes in healthy subjects. We will carry out a partial correlation analysis of levels, state anxiety and trait anxiety, and then a similar analysis of slopes, state anxiety and trait anxiety. These results may show that concrete skin conductance levels and slopes are related to metrics of subjective self report measures of state and trait anxiety.
Study NCT02363374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Chemotherapy arm A
Description: Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71
Study NCT02363374 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation arm A
Description: Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
Study NCT02363374 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation arm B
Description: Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
Study NCT02363374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy arm B
Description: chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
Study NCT02363374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
Study NCT02363374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
Study NCT00545220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem-solving training
Study NCT00545220 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Study NCT04231214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol-Tiotropium
Description: 5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
Study NCT01340781 — intervention group
Intervention type: PROCEDURE
Intervention: Polysomnogram
Description: An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
Study NCT04612543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genial Posterior Composite with Polyethylene Fiber
Description: Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
Study NCT04612543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genial Posterior Composite
Description: Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
Study NCT00094718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN/DEN4-3'delta30
Description: Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
Study NCT00094718 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for WN/DEN4-3'delta30 vaccine
Study NCT01247532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction - Cancer-Related Fatigue
Description: 7 week 2 hour class
Study NCT06284616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASP-1
Description: patients following the Juvenile Arthritis Support Program at the Pediatric Rheumatology Clinic
Study NCT02189499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Description: Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
Study NCT02863523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Care
Description: Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
Study NCT01120314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTAMIXABAN (XRP0673)
Description: Form: solution for injection~Route: intravenous
Study NCT02798770 — intervention group
Intervention type: OTHER
Intervention: No Intervention Foreseen
Study NCT01221025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
Study NCT01344629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipin FDC
Description: Telmisartan80mg/Amlodipin5mg FDC
Study NCT00729989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric suctioning
Description: The stomach will be suctioned shortly following birth with an orogastric tube
Study NCT03198533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon PA
Description: Implantation of Knee Prosthesis
Study NCT03198533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon Pressfit
Description: Implantation of Knee Prosthesis
Study NCT02255981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and massage
Description: Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself.
Study NCT02650505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204
Study NCT02650505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 43204 Vehicle
Study NCT01344629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 80 mg tablet
Study NCT01344629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipin
Description: Amlodipin 5mg tablet
Study NCT00900146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
Study NCT00478244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Day -5 through Day -2: 50 mg/kg IV over 120 min.
Study NCT00478244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Day -5 through Day -3: 25 mg/m2 IV over 60 min.
Study NCT00478244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic bone marrow transplantation
Description: allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
Study NCT01954745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
Study NCT04366687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Parents - Safe and Healthy Kids
Description: Smart Parents - Safe and Healthy Kids (SPHSK) is a module designed to be added to existing evidence-based parent education programs. Because the module builds off of the core parenting skills developed in existing parent education programs, the module can be delivered in one session. SPSHK is comprised of three key CSA-prevention components: healthy child sexual development, parent-child communication about sex and sexual behaviors, and CSA-specific safety strategies such as vetting a babysitter and monitoring one-on-one time with adults. Behaviorally based, the module presents developmentally comprehensive information to parents of children 0-13 and utilizes role-playing scenarios and activities to maximize parents' use of learned skills.
Study NCT04366687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Teachers
Description: Parents as Teachers (PAT) is a parent-support program delivered to parents of children under five and focuses on improving parenting skills through parent-child interactions, development centered parenting, and general well-being. PAT has demonstrated positive effects on child and parent outcomes related to school readiness.
Study NCT04030715 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bismuth-containing quadral therapy based on antibiotic susceptibility
Description: the different mucosal pathology graded by New Sydney System
Study NCT00233402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexvix
Description: Single Instillation, Transurethral Resection of the Bladder
Study NCT00233402 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard white light cystoscopy
Study NCT00233402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard white light cystoscopy
Study NCT01887171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
Study NCT00900146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
Study NCT01589718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen
Description: one intravitreal injection of Macugen prior to vitrectomy surgery
Study NCT01589718 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
Study NCT02723747 — intervention group
Intervention type: OTHER
Intervention: myocardial perfusion with magnetic resonance imaging
Study NCT00900146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
Study NCT00900146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
Study NCT01811303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D-fagomine
Description: Measure the changes produced on the postprandial Glycaemic response
Study NCT01811303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-fagomine
Description: Measure the changes produced on the postprandial Glycaemic response
Study NCT04326036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)
Description: Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
Study NCT04326036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
Study NCT04326036 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Centricyte 1000
Description: Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
Study NCT04326036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV Deployment Of cSVF In Sterile Normal Saline IV Solution
Description: Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
Study NCT04326036 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: IV Deployment Of cSVF In Sterile Normal Saline IV Solution
Description: Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
Study NCT03564106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraarticular radiofrequency + intraarticular methylprednisolone
Description: intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)